Tay-Sachs disease is a rare, inherited condition in which the body lacks an enzyme needed to break down fatty substances in the brain. Without this enzyme, those fatty substances build up in nerve cells and progressively destroy them, causing severe neurological decline. The most common form appears in infancy and is fatal, but rarer forms can emerge in childhood or adulthood with milder, slower-progressing symptoms.
What Happens in the Body
Your nerve cells constantly produce and recycle fatty molecules called gangliosides as part of normal brain function. A specific enzyme breaks these molecules down once they’ve served their purpose. In Tay-Sachs, a mutation in the HEXA gene means the body produces little or none of this enzyme. The unprocessed gangliosides pile up inside neurons, swelling and eventually killing them.
This accumulation is relentless. Once nerve cells are damaged, they don’t regenerate. The disease primarily targets the brain and spinal cord, which is why the symptoms are neurological: lost movement, lost cognition, seizures.
How Tay-Sachs Is Inherited
Tay-Sachs follows an autosomal recessive pattern. That means a child must inherit a defective copy of the HEXA gene from both parents to develop the disease. If both parents carry one defective copy, each pregnancy carries a 25% chance the child will have Tay-Sachs, a 50% chance the child will be a carrier (healthy but able to pass the gene on), and a 25% chance the child will inherit no defective copies at all.
Carriers produce enough of the enzyme to stay healthy and typically have no idea they carry the gene unless they’re tested. Carrier frequency varies significantly by population. Among people of Ashkenazi Jewish descent, roughly 1 in 30 individuals is a carrier. French-Canadian and Cajun populations also have elevated carrier rates. In the general population, the rate is considerably lower, though the disease can occur in any ethnic group.
Infantile Tay-Sachs
The classic and most common form appears in infancy. Babies develop normally for the first few months of life, then begin showing signs between 3 and 6 months of age. One of the earliest symptoms parents notice is an exaggerated startle response to loud noises. Over the following months, the baby starts losing motor skills they had already gained, such as rolling over, crawling, and sitting up.
The decline accelerates. Seizures develop. Vision and hearing deteriorate. The child becomes increasingly unresponsive to the surrounding environment. One characteristic physical finding, present in roughly 75 to 90 percent of infantile cases, is a cherry-red spot visible on the retina during an eye exam. This spot appears because the disease causes fatty deposits to build up in the retinal nerve cells, turning the surrounding tissue white, while the center of the retina (which lacks those cells) remains its normal reddish color, creating a stark contrast.
Children with the infantile form typically do not survive past early childhood. There is currently no cure or treatment that can reverse the damage.
Juvenile and Adult-Onset Forms
Less common forms of Tay-Sachs appear later in life, driven by HEXA mutations that leave the body with some residual enzyme activity rather than none at all. The more enzyme a person produces, the later symptoms tend to appear and the slower they progress.
The juvenile form begins in childhood and shares many features with the infantile version, including gradual loss of motor skills, declining mental function, and seizures, but the timeline is stretched out over years rather than months.
Late-onset Tay-Sachs (sometimes called LOTS) can appear anywhere from late childhood into adulthood. Its presentation looks quite different from the infantile form. Muscle weakness, clumsiness, tremors, and muscle spasms are common. Many adults with LOTS experience problems with coordination and balance due to dysfunction in the part of the brain that controls movement. Psychiatric symptoms, including depression and psychosis, can also appear, which sometimes leads to misdiagnosis before the underlying cause is identified. LOTS is extremely rare, particularly outside of Ashkenazi Jewish populations, and progresses slowly enough that many people live for decades after diagnosis.
How It’s Diagnosed
Diagnosis involves two main tools. A blood test measures the activity level of the missing enzyme. In people with Tay-Sachs, enzyme levels are either extremely low or completely absent. In carriers, levels are reduced but still functional. Genetic testing can examine the HEXA gene directly to identify the specific mutations involved. This is particularly useful for confirming carrier status or when enzyme test results are inconclusive.
For pregnant women or those taking oral contraceptives, enzyme testing needs to be done using white blood cells rather than serum (the liquid part of blood), because hormonal changes can produce false-positive results with standard serum testing.
Carrier Screening Before Pregnancy
Because carriers have no symptoms, screening is the only way to know your risk before having children. The American College of Obstetricians and Gynecologists recommends that carrier screening ideally happen before pregnancy, giving couples time to understand their options.
Screening is specifically recommended for anyone of Ashkenazi Jewish, French-Canadian, or Cajun descent, and for anyone with a family history of Tay-Sachs. When one partner is in a high-risk group and the other is not, the high-risk partner should be tested first. If that person turns out to be a carrier, the other partner should then be tested as well.
Some couples encounter Tay-Sachs screening as part of broader expanded carrier panels that test for dozens of conditions at once. These panels work well for many diseases, but they may not catch every HEXA mutation, particularly in people outside the Ashkenazi Jewish population. If you have a family history of Tay-Sachs, a targeted test that includes the specific mutation in your family is more reliable than a generic panel.
Treatment and Gene Therapy Progress
No approved treatment currently exists that can stop or reverse Tay-Sachs. Care for infantile cases focuses on keeping the child as comfortable as possible, managing seizures, ensuring adequate nutrition, and supporting families through the process.
Gene therapy research, however, has produced encouraging early results. A Phase I/II clinical trial at UMass Chan Medical School tested a gene therapy approach in nine patients with GM2 gangliosidosis (the broader disease category that includes Tay-Sachs). The treatment used two harmless viral carriers injected into the brain and spinal cord, delivering genetic instructions that teach brain cells to produce the missing enzyme. All participants showed increased enzyme production, with activity levels rising above twice the lower limit of normal.
The practical effects were meaningful, if modest. Ordinarily, more than half of children with this condition need a feeding tube between 13 and 18 months of age. In the trial, half the treatment groups stayed on full oral feeding for at least 25 months, and the two patients who received the highest doses maintained oral feeding through the end of the study. Seizures appeared later, were less severe, and responded better to medication. Researchers noted that while they didn’t achieve fully therapeutic enzyme levels, the approach proved safe and the gene therapy vectors worked as intended. Larger trials at higher doses are the next step.